New application of artemisinin derivatives and metal ion chelators in the synergist of polymyxin antibiotics
Through the combined use of artemisinin derivatives and metal ion complexing agents, the problem of reducing the antibacterial activity of polymyxin antibiotics on drug-resistant bacteria is solved, and the minimum inhibitory concentration is significantly reduced, achieving effective against drug-resistant bacteria Treatment reduces the side effects of drug toxicity and has important clinical application value.
Patent Information
- Application Number
- CN202310325618.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-30
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-03-30
AI Technical Summary
The antibacterial activity of polymyxin antibiotics on drug-resistant bacteria has decreased, resulting in increased treatment difficulty, and their neurotoxicity and nephrotoxicity cannot be ignored. A synergist is needed to reduce the dosage of the drug and restore the antibacterial effect.
Artemisinin derivatives (such as artesunate) are used in combination with metal ion complexing agents (such as EDTA-2Na) as synergists for polymyxin antibiotics, which significantly reduces polymyxin by optimizing the ratio. Minimum inhibitory concentration to enhance its antibacterial activity against drug-resistant bacteria.
It significantly reduces the minimum antibacterial concentration of polymyxin on drug-resistant bacteria, reduces the side effects of drug toxicity, and ensures effective treatment of drug-resistant bacteria, which has important clinical application value.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to a new use of an artemisinin derivative and a metal ion complexing agent in a polymyxin antibiotic synergist. Background Art
[0002] Polymyxin antibiotics are cationic polypeptides with antibacterial activity. They were first isolated from soil bacteria Bacillus polymyxa subspecies in 1947. They can be divided into 8 types according to their chemical structure, namely polymyxin A, B, C, D, E, K, M and P. Among them, polymyxin B (Polymycin B) and polymyxin E (also known as colistin, Polymycin E, Colistin, COL) are commonly used in clinical treatment. Polymyxin has a positive charge and can react with G — The negatively charged lipid A in the bacterial cell outer membrane interacts with and replaces Ca 2+ and Mg 2+ Polymyxins are nephrotoxic and neurotoxic, so in the 1970s, β-lactams, quinolones, and aminoglycosides replaced polymyxins for clinical treatment. However, in recent years, with the increasing resistance of bacteria to β-lactams, quinolones, and aminoglycosides, polymyxins have been reapplied to clinical treatment. Polymyxins are considered to be a good choice for the treatment of multidrug-resistant (MDR) G — Polymyxin is the last line of defense against MDR bacterial infections. However, as its clinical application gradually increases, bacterial resistance to polymyxin is becoming increasingly serious, and humans will face a situation where no drugs are available. Combination therapy, as a new drug strategy, is of great significance for the treatment of MDR bacterial infections. In addition, although polymyxin is resistant to G — It has a good killing effect on bacteria, but its neurotoxicity and nephrotoxicity in clinical practice cannot be ignored. In addition, the phenomenon of bacterial resistance to polymyxin is increasing. Therefore, while reducing the dosage, the combined use of enhancers and polymyxins to increase its antibacterial activity against resistant strains has important clinical application value.
[0003] Artemisia annua is bitter and pungent in taste, cold in nature, and enters the liver and gallbladder meridians. It has the effects of clearing away heat from the deficiency, removing bone steaming, relieving summer heat, stopping malaria, and relieving jaundice. It is the first choice for clinical clearing away heat from the deficiency and has a long history of application in China. Artemisinin is a sesquiterpene trioxane lactone antimalarial drug extracted from Artemisia annua. It was isolated from Artemisia annua by the team of Chinese scientist Tu Youyou in 1972 and can effectively eliminate parasites in malaria animal models. Subsequently, various derivatives of artemisinin such as artesunate, dihydroartemisinin, and artemether have been introduced. Artesunate has good antiparasitic, antiviral, antifungal, antitumor, anti-inflammatory, antioxidant, antiangiogenic and immunomodulatory effects. However, in areas where artemisinin is used as a monotherapy in clinical studies, resistance to artemisinin and artesunate has emerged. At present, many studies have shown that artemisinin and artesunate combined with a variety of antibacterial drugs, such as β-lactams, daunomycin, oxacillin, sulpacillin and cefpiramide, can exhibit significant antibacterial and synergistic effects. However, when artemisinin or artesunate is used as an antibacterial adjuvant for polymyxin, the antibacterial and synergistic effect is not significant when used in combination with polymyxin.
[0004] Artesunate (C 19 H 28 The structural formula of O8 is shown below.
[0005]
[0006] In the prior art, Chinese patents CN101380325A, CN102309501A and CN102309500A respectively disclose artemisinin derivatives (dihydroartemisinin, artesunate or C 24 H 41 The invention discloses that the present invention improves the anti-tumor efficacy of chemotherapy after the combination of vinorelbine, doxorubicin or cisplatin with artemisinin (O9N) belongs to the field of sensitizing drugs for tumor chemotherapy, which is different from the implementation subject and the purpose of the present invention; Chinese patents CN113082026A and CN113181176A disclose the use of an artemisinin derivative DHA27 in the preparation of a polymyxin, gentamicin, imipenem and ciprofloxacin anti-Pseudomonas aeruginosa synergist, wherein DHA27 is a novel artemisinin derivative obtained by modifying its side chains on the basis of artesunate while retaining the parent core structure, which is different from the implementation subject and the object of the present invention; Chinese patent CN112245566B discloses the combination of scutellaria baicalensis flavonoids and metal ion chelating agents to provide a new use as a polymyxin synergist, which is different from the implementation subject and the synergistic effect of the present invention, and the synergistic effect of the present invention is more significant. Summary of the invention
[0007] The purpose of the present invention is to provide a new use of the combination of artemisinin derivatives and metal ion complexing agents as a polymyxin antibiotic synergist, so as to reduce the dosage of polymyxin antibiotics, restore the antibacterial effect of the drugs on drug-resistant bacteria, and effectively treat bacterial infections, especially drug-resistant bacterial infections.
[0008] The artemisinin derivative is at least one of artemether, arteether, artesunate and dihydroartemisinin, preferably artesunate.
[0009] The polymyxin antibiotic or polymyxin is colistin (i.e. polymyxin E) or polymyxin B.
[0010] The metal ion complexing agent is at least one of EDTA-2Na (disodium edetate), EDTACa-Na2 (calcium sodium edetate), sodium tripolyphosphate and sodium hexametaphosphate.
[0011] The dosage of artesunate is 156.2-312.5 μg / mL, and the dosage of the metal ion complexing agent is 15.5-125 μg / mL. When the artemisinin derivative and the metal ion complexing agent are used to prepare a composition or a compound preparation to enhance the antibacterial effect of polymyxin antibiotics, the mass ratio of colistin, artesunate and EDTA-2Na is 0.015-0.5:156.2-312.5:15.5-125.
[0012] The experiment showed that compared with the single drug polymyxin, when polymyxin antibiotics were used in combination with artemisinin derivatives or metal ion chelators, the minimum inhibitory concentration (MIC) of polymyxin against strains could be reduced by 2 to 16 times, and when polymyxin antibiotics were used in combination with artemisinin derivatives and metal ion chelators, the antibacterial activity of polymyxin could be significantly enhanced (MIC decreased by 8 to 66667 times), indicating that the use of artemisinin derivatives and metal ion chelators as polymyxin enhancers in the present invention can effectively reverse the resistance of resistant bacteria to polymyxin, and can greatly reduce the dosage of antibacterial drugs in clinical practice, and can ensure its antibacterial therapeutic effect on resistant bacteria.
[0013] The present invention opens up a new use for the combined use of artemisinin derivatives and metal ion chelating agents. As a synergist of polymyxin antibiotics, the dosage of polymyxin antibiotics can be reduced, thereby reducing the toxic and side effects of the drugs, restoring the antibacterial effect of the drugs on drug-resistant bacteria, and effectively treating bacterial infections, especially drug-resistant bacterial infections, and has important clinical application value. Implementation
[0014] The present invention will be further described below in conjunction with the embodiments, but the protection scope of the present invention is not limited to the following embodiments. Example
[0015] The antibacterial effect of colistin (polymyxin E) and artemisinin derivatives and metal ion chelator EDTA-2Na against clinical isolate ST30 of Salmonella was investigated. Materials and methods are as follows:
[0016] 1. Drug testing:
[0017] Artesunate (ART): produced by Dalian Meilun Biotechnology Co., Ltd., content: >98%. Colistin (COL): produced by Hebei Shengxue Dacheng Tangshan Pharmaceutical Co., Ltd., potency ≥23000 u / mg. EDTA-2Na: produced by Sinopharm Chemical Reagent Co., Ltd.
[0018] Artesunate was prepared with deionized water to a concentration of 5000 μg / mL, and 10% (V / V) N, N-dimethylformamide was added to aid dissolution. EDTA-2Na was prepared with deionized water to a concentration of 10000 μg / mL. Colistin was prepared with deionized water to a concentration of 640 μg / mL. EDTA-2Na and colistin were stored at -20°C. Before the test, the drug storage solution was taken out and melted at room temperature, and then fully mixed. Artesunate was prepared and used immediately, and pharmacodynamic tests were performed separately.
[0019] 2. Strains:
[0020] Clinically isolated Salmonella strains: Salmonella ST30 was provided by the Pharmacology Laboratory of Henan Agricultural University and was identified by PCR and mass spectrometry (MALDI-TOF / MS). Salmonella was activated by streaking on SS medium, cultured at 37°C for 16-18h, and stored at 4°C for later use.
[0021] 3. Culture medium:
[0022] LB broth medium: produced by Beijing Aoboxing Biotechnology Co., Ltd., prepare 1000 ml according to the instructions of this product, sterilize at 121℃ for 15 minutes, and store at 4℃ for later use. SS agar medium: produced by Beijing Aoboxing Biotechnology Co., Ltd., prepare 1000 ml according to the instructions of this product, heat and boil to fully dissolve and sterilize, cool to 60℃ and pour into sterilized plates and store at 4℃ for later use. MHB broth medium: produced by Beijing Aoboxing Biotechnology Co., Ltd., prepare 1000 ml according to the instructions of this product, sterilize at 121℃ for 15 minutes, and store at 4℃ for later use.
[0023] 4. Instruments:
[0024] High-pressure steam autoclave (Shanghai Shen'an Medical Instrument Factory); AB204-N electronic analytical balance (Mettler-Tolly Instrument Shanghai Co., Ltd.); HZQ-R air bath oscillator (Beijing Liuyi Instrument Factory); DH-600 electric constant temperature incubator (Beijing Kewei Yongxing Instrument Co., Ltd.); DHG-9140A vacuum drying oven (Shanghai Yiheng Experimental Instrument Co., Ltd.); SW-CJ-JC clean bench (Suzhou Antai Air Technology Co., Ltd.).
[0025] 5. Preparation of bacterial solution
[0026] Pick a single colony of Salmonella from the SS medium stored at 4°C, inoculate it into 5 mL of LB broth medium, and culture it at 37°C with shaking at 180 rpm to activate the bacteria in the late exponential growth phase. Take the bacterial solution into MHB broth medium and dilute the original bacterial solution to 10 5 CFU / mL. The corresponding concentrations of artesunate (312.5 or 156.2 μg / mL, i.e. 1 / 4 or 1 / 8 MIC) were added to the bacterial suspension. ART ) and EDTA-2Na (31.2 and 15.5 μg / mL, i.e. 1 / 4 and 1 / 8 of the MIC EDTA )spare.
[0027] Combination therapy: 1 / 4 MIC ART + Colistin, 1 / 8 MIC ART + Colistin, 1 / 4 MIC EDTA + Colistin, 1 / 8 MIC EDTA + Colistin.
[0028] Three-drug combination regimen: 1 / 4 MIC ART + 1 / 4MIC EDTA + Colistin, 1 / 4 MIC ART + 1 / 8MIC EDTA + Colistin, 1 / 8 MIC ART + 1 / 4 MIC EDTA + Colistin, 1 / 8 MIC ART + 1 / 8 MIC EDTA + Colistin.
[0029] 6. Preparation of drug sensitivity plate:
[0030] Use the bacterial suspension in step 5 for drug sensitivity test. Take a sterile 96-well reaction plate, add 126 μL of freshly prepared bacterial suspension containing artesunate or EDTA-2Na and 14 μL of colistin (640 μg / mL) to well 1 in the first row; add 70 μL of freshly prepared bacterial suspension containing artesunate and EDTA-2Na to wells 2-12; add 70 μL of freshly prepared bacterial suspension containing artesunate or EDTA-2Na to wells 1-8 in the second row, and add 70 μL of MHB broth to well 9 as a blank control. The wells 1-12 in the first row and 1-7 in the second row were serially diluted so that the final colistin concentrations in the wells 1-12 in the first row and 1-7 in the second row were 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.063, 0.031, 0.016, 0.008, 0.004, 0.002, 0.001, 0.0005, and 0.0003 μg / mL, respectively; well 8 in the second row was the MHB bacterial suspension without colistin as a negative control; well 9 was the bacterial solution without drug as a positive control, and the drug sensitivity plate was incubated at 37°C for 16-20 h.
[0031] 7. Determination of minimum inhibitory concentration (MIC):
[0032] After the 96-well plate containing bacteria was incubated at 37°C for 16-20 h, the MIC results were read. The drug MIC value is the drug concentration in the clear and transparent well before the turbid well in the 96-well plate. The above experiments were performed in parallel 3 times, and the MIC values were accepted only when they could be accurately repeated; when the MIC values differed by more than one concentration, a new test was required until the requirements were met. The results are shown in Table 1.
[0033]
[0034] As shown in Table 1, the MIC value of colistin against strain ST30 was 4 μg / mL, the MIC value of artesunate against strain ST30 was 1250 μg / mL, and the MIC value of EDTA-2Na against strain ST30 was 125 μg / mL.
[0035] When artesunate or EDTA-2Na was combined with colistin, the MIC of colistin was 0.25 and 0.5 μg / mL when 1 / 4 MIC (312.5 μg / mL) and 1 / 8 MIC (156.2 μg / mL) of ART were added, respectively, which were 16 and 8 times lower than the MIC of colistin alone; when 1 / 4 MIC (31.2 μg / mL) and 1 / 8 MIC (15.5 μg / mL) of EDTA-2Na were added, the MIC of colistin was 2 μg / mL, which was 2 times lower than the MIC of colistin alone.
[0036] When artesunate and EDTA-2Na were combined with colistin, the MICs of colistin were 0.03 and 0.25 μg / mL, respectively, when artesunate at 1 / 4 MIC concentration and EDTA-2Na at 1 / 4 MIC and 1 / 8 MIC concentrations were used in combination, which were 133 and 16 times lower than the MIC of colistin used alone; when artesunate at 1 / 8 MIC concentration and EDTA-2Na at 1 / 4 MIC and 1 / 8 MIC concentrations were used in combination, the MICs of colistin were 0.125 and 0.25 μg / mL, respectively, which were 32 and 16 times lower than the MIC of colistin used alone.
[0037] It can be concluded from Table 1 that when the concentration of artesunate is between 156.2 and 312.5 μg / mL and the concentration of EDTA-2Na is between 15.5 and 31.2 μg / mL, the combined use of artesunate and EDTA-2Na can significantly enhance the antibacterial activity of colistin against clinically isolated Salmonella ST30. Example
[0038] The antibacterial effect of colistin (polymyxin E) and artemisinin derivatives and metal ion chelator EDTA-2Na against clinically isolated Salmonella ST23 was investigated. Materials and methods are as follows:
[0039] 1. Drug testing:
[0040] Same as Example 1.
[0041] 2. Strains:
[0042] Clinically isolated Salmonella strains: Salmonella ST23 was provided by the Pharmacology Laboratory of Henan Agricultural University and was identified by PCR and mass spectrometry (MALDI-TOF / MS). Salmonella was activated by streaking on SS medium, cultured at 37°C for 16-18 h, and stored at 4°C for later use.
[0043] 3. Culture medium:
[0044] Same as Example 1.
[0045] 4. Instruments:
[0046] Same as Example 1.
[0047] 5. Preparation of bacterial solution:
[0048] Same as Example 1.
[0049] 6. Preparation of drug sensitivity plate:
[0050] Same as Example 1.
[0051] 7. Determination of MIC value:
[0052] After the 96-well plate containing bacteria was incubated at 37°C for 16-20 h, the MIC results were read. The drug MIC value is the drug concentration in the clear and transparent well before the turbid well in the 96-well plate. The above experiments were performed in parallel 3 times, and the MIC values were accepted only when they could be accurately repeated; when the MIC values differed by more than one concentration, a new test was required until the requirements were met. The results are shown in Table 2.
[0053]
[0054] As shown in Table 2, the MIC value of colistin against strain ST23 was 4 μg / mL, the MIC value of artesunate against strain ST23 was 1250 μg / mL, and the MIC value of EDTA-2Na against strain ST23 was 125 μg / mL.
[0055] When artesunate or EDTA-2Na was combined with colistin, the MIC of colistin was 0.25 and 0.5 μg / mL when 1 / 4 MIC (312.5 μg / mL) and 1 / 8 MIC (156.2 μg / mL) of artesunate were added, which were 16 and 8 times lower than the MIC of colistin alone. When 1 / 4 MIC (31.2 μg / mL) and 1 / 8 MIC (15.5 μg / mL) of EDTA-2Na were added, the MIC of colistin was 2 μg / mL, which was 2 times lower than the MIC of colistin alone.
[0056] When artesunate and EDTA-2Na were combined with colistin, the MICs of colistin were 0.0625 and 0.125 μg / mL, respectively, when artesunate at 1 / 4 MIC concentration and EDTA-2Na at 1 / 4 MIC and 1 / 8 MIC concentrations were used in combination, which were 64 and 32 times lower than the MIC of colistin alone; when ART at 1 / 8 MIC concentration and EDTA-2Na at 1 / 4 MIC and 1 / 8 MIC concentrations were used in combination, the MICs of colistin were 0.125 and 0.25 μg / mL, respectively, which were 32 and 16 times lower than the MIC of colistin alone.
[0057] It can be concluded from Table 2 that when the concentration of artesunate is between 156.2 and 312.5 μg / mL and the concentration of EDTA-2Na is between 15.5 and 31.2 μg / mL, the combined use of artesunate and EDTA-2Na can significantly enhance the antibacterial activity of colistin against clinically isolated Salmonella ST23. Example
[0058] The antibacterial effect of colistin (polymyxin E) and artemisinin derivatives and metal ion chelator EDTA-2Na against clinical isolate ST293 of Salmonella was investigated. Materials and methods are as follows:
[0059] 1. Drug testing:
[0060] Same as Example 1.
[0061] 2. Strains:
[0062] Clinically isolated Salmonella strains: Salmonella ST293 was provided by the Pharmacology Laboratory of Henan Agricultural University and was identified by PCR and mass spectrometry (MALDI-TOF / MS). Salmonella was activated by streaking on SS medium, cultured at 37°C for 16-18h, and stored at 4°C for later use.
[0063] 3. Culture medium:
[0064] Same as Example 1.
[0065] 4. Instruments:
[0066] Same as Example 1.
[0067] 5. Preparation of bacterial solution:
[0068] Same as Example 1.
[0069] 6. Preparation of drug sensitivity plate:
[0070] Same as Example 1.
[0071] 7. Determination of MIC value:
[0072] After the 96-well plate containing bacteria was incubated at 37°C for 16-20 h, the MIC results were read. The drug MIC value is the drug concentration in the clear and transparent well before the turbid well in the 96-well plate. The above experiments were performed in parallel 3 times, and the MIC values were accepted only when they could be accurately repeated; when the MIC values differed by more than one concentration, a new test was required until the requirements were met. The results are shown in Table 3.
[0073]
[0074] As shown in Table 3, the MIC value of colistin against strain ST293 was 4 μg / mL, the MIC value of artesunate against strain ST293 was 1250 μg / mL, and the MIC value of EDTA-2Na against strain ST293 was 125 μg / mL.
[0075] When artesunate or EDTA-2Na was combined with colistin, the MIC of colistin was 0.25 and 2 μg / mL when 1 / 4 MIC (312.5 μg / mL) and 1 / 8 MIC (156.2 μg / mL) of artesunate were added, which were 16 and 2 times lower than the MIC of colistin alone. When 1 / 4 MIC (31.2 μg / mL) and 1 / 8 MIC (15.5 μg / mL) of EDTA-2Na were added, the MIC of colistin was 2 μg / mL, which was 2 times lower than the MIC of colistin alone.
[0076] When ART and EDTA-2Na were combined with colistin, the MICs of colistin were 0.03 and 0.0625 μg / mL, respectively, when artesunate at 1 / 4 MIC and EDTA-2Na at 1 / 4 MIC and 1 / 8 MIC were used in combination, which were 133 and 64 times lower than the MIC of colistin alone; when artesunate at 1 / 8 MIC and EDTA-2Na at 1 / 4 MIC and 1 / 8 MIC were used in combination, the MICs of colistin were 0.25 and 0.5 μg / mL, respectively, which were 16 and 8 times lower than the MIC of colistin alone.
[0077] It can be concluded from Table 3 that when the concentration of artesunate is between 156.2 and 312.5 μg / mL and the concentration of EDTA-2Na is between 15.5 and 31.2 μg / mL, the combined use of artesunate and EDTA-2Na can significantly enhance the antibacterial activity of colistin against clinically isolated Salmonella ST293. Example
[0078] The antibacterial effect of colistin (polymyxin E) and artemisinin derivatives and metal ion chelator EDTA-2Na against clinical isolate ST134 of Salmonella was investigated. Materials and methods are as follows:
[0079] 1. Drug testing:
[0080] Same as Example 1.
[0081] 2. Strains:
[0082] Clinically isolated Salmonella strains: Salmonella ST134 was provided by the Pharmacology Laboratory of Henan Agricultural University and was identified by PCR and mass spectrometry (MALDI-TOF / MS). Salmonella was activated by streaking on SS medium, cultured at 37°C for 16-18h, and stored at 4°C for later use.
[0083] 3. Culture medium:
[0084] Same as Example 1.
[0085] 4. Instruments:
[0086] Same as Example 1.
[0087] 5. Preparation of bacterial solution:
[0088] Same as Example 1.
[0089] 6. Preparation of drug sensitivity plate:
[0090] Same as Example 1.
[0091] 7. Determination of MIC value:
[0092] After the 96-well plate containing bacteria was incubated at 37°C for 16-20 h, the MIC results were read. The drug MIC value is the drug concentration in the clear and transparent well before the turbid well in the 96-well plate. The above experiments were performed in parallel 3 times, and the MIC values were accepted only when they could be accurately repeated; when the MIC values differed by more than one concentration, a new test was required until the requirements were met. The results are shown in Table 4.
[0093] As shown in Table 4, the MIC value of colistin against strain ST134 was 2 μg / mL, the MIC value of artesunate against strain ST134 was 1250 μg / mL, and the MIC value of EDTA-2Na against strain ST134 was 125 μg / mL.
[0094] When artesunate or EDTA-2Na was combined with colistin, the MIC of colistin was 0.25 μg / mL when 1 / 4 MIC (312.5 μg / mL) and 1 / 8 MIC (156.2 μg / mL) of ART were added, which was 8 times lower than the MIC of colistin alone. When 1 / 4 MIC (31.2 μg / mL) and 1 / 8 MIC (15.5 μg / mL) of EDTA-2Na were added, the MIC of colistin was 1 and 2 μg / mL, respectively, which was 4 and 2 times lower than the MIC of colistin alone.
[0095] When artesunate and EDTA-2Na were combined with colistin, the MICs of colistin were 0.015 and 0.125 μg / mL, respectively, when artesunate at 1 / 4 MIC concentration and EDTA-2Na at 1 / 4 MIC and 1 / 8 MIC concentrations were used in combination, which were 133 and 16 times lower than the MIC of colistin used alone; when artesunate at 1 / 8 MIC concentration and EDTA-2Na at 1 / 4 MIC and 1 / 8 MIC concentrations were used in combination, the MICs of colistin were 0.0625 and 0.25 μg / mL, respectively, which were 32 and 8 times lower than the MIC of colistin used alone.
[0096] It can be concluded from Table 4 that when the concentration of artesunate is between 156.2 and 312.5 μg / mL and the concentration of EDTA-2Na is between 15.5 and 31.2 μg / mL, the combined use of artesunate and EDTA-2Na can significantly enhance the antibacterial activity of colistin against clinically isolated Salmonella ST134. Example
[0097] The antibacterial effect of colistin (polymyxin E) and artemisinin derivatives and metal ion chelator EDTA-2Na against Escherichia coli clinical isolate 16R was investigated. Materials and methods are as follows:
[0098] 1. Drug testing:
[0099] Same as Example 1.
[0100] 2. Strains:
[0101] Clinically isolated Escherichia coli: Escherichia coli 16R was provided by the Pharmacology Laboratory of Henan Agricultural University and was identified by PCR and mass spectrometry (MALDI-TOF / MS). Escherichia coli was activated by streaking on MacConkey agar medium and cultured at 37°C for 12-16 h and stored at 4°C for later use.
[0102] 3. Culture medium:
[0103] LB broth medium: produced by Beijing Aoboxing Biotechnology Co., Ltd., prepare 1000 ml according to the instructions of this product, sterilize at 121℃ for 15 minutes, and store at 4℃ for later use. MacConkey agar medium: produced by Beijing Aoboxing Biotechnology Co., Ltd., prepare 1000 ml according to the instructions of this product, sterilize at 121℃ for 15 minutes, cool to 60 degrees, pour into sterilized plates and store at 4℃ for later use. MHB broth medium: produced by Beijing Aoboxing Biotechnology Co., Ltd., prepare 1000 ml according to the instructions of this product, sterilize at 121℃ for 15 minutes, and store at 4℃ for later use.
[0104] 4. Instruments:
[0105] Same as Example 1.
[0106] 5. Preparation of bacterial solution:
[0107] Pick a single colony of E. coli from the MacConkey medium stored at 4°C, inoculate it into 5 mL of LB broth, and culture it at 37°C with shaking at 180 rpm to activate the bacteria in the late exponential growth phase. Take the bacterial solution into MHB broth and dilute the original bacterial solution to 10 5 CFU / mL to prepare bacterial suspension. The corresponding concentration of artesunate (312.5 or 156.2 μg / mL, i.e. 1 / 4 or 1 / 8 MIC) was added to the bacterial suspension. ART) and EDTA-2Na (125 and 62.5 μg / mL, i.e. 1 / 4 and 1 / 8 MIC EDTA The drug combination scheme is the same as in Example 1.
[0108] 6. Preparation of drug sensitivity plate:
[0109] Same as Example 1.
[0110] 7. Determination of MIC value:
[0111] After the 96-well plate containing bacteria was incubated at 37°C for 16-20 h, the MIC results were read. The drug MIC value is the drug concentration of the clear and transparent well before the turbid well in the 96-well plate. The above experiments were performed in parallel 3 times, and the MIC values were accepted only when they could be accurately repeated; when the MIC values differed by more than one concentration, a new test was required until the requirements were met. The results are shown in Table 5.
[0112] As shown in Table 5, the MIC value of colistin against strain 16R was 2 μg / mL, the MIC value of artesunate against strain 16R was 1250 μg / mL, and the MIC value of EDTA-2Na against strain 16R was 500 μg / mL.
[0113] When artesunate or EDTA-2Na was combined with colistin, the MIC of colistin was 0.5 μg / mL when 1 / 4 MIC (312.5 μg / mL) and 1 / 8 MIC (156.2 μg / mL) of artesunate were added, which was 4 times lower than the MIC of colistin alone; when 1 / 4 MIC (125 μg / mL) and 1 / 8 MIC (62.5 μg / mL) of EDTA-2Na were added, the MIC of colistin was 0.5 μg / mL, which was 4 times lower than the MIC of colistin alone.
[0114] When artesunate and EDTA-2Na were combined with colistin, the MICs of colistin were 0.00003 and 0.002 μg / mL, respectively, when 1 / 4 MIC concentration of ART and 1 / 4 MIC and 1 / 8 MIC concentrations of EDTA-2Na were used in combination, which were 66667 and 1000 times lower than the MIC of colistin alone; when 1 / 8 MIC concentration of artesunate and 1 / 4 MIC and 1 / 8 MIC concentrations of EDTA-2Na were used in combination, the MICs of colistin were 0.004 and 0.015 μg / mL, respectively, which were 500 and 133 times lower than the MIC of colistin alone.
[0115] It can be concluded from Table 5 that when the concentration of artesunate is between 156.2 and 312.5 μg / mL and the concentration of EDTA-2Na is between 62.5 and 125 μg / mL, the combined use of artesunate and EDTA-2Na can significantly enhance the antibacterial activity of colistin against clinically isolated Escherichia coli 16R.
Claims
1. A polymyxin antibiotic synergist, characterized in that: Comprising an artemisinin derivative and a metal ion complexing agent; the dosage of the artemisinin derivative is 156.2 to 312.5 μg / mL, and the dosage of the metal ion complexing agent is 15.5 to 125 μg / mL; The artemisinin derivative is artesunate; The polymyxin antibiotic is colistin; The metal ion complexing agent is EDTA-2Na.
2. A polymyxin antibiotic compound preparation, characterized in that: It includes polymyxin, artemisinin derivatives, and metal ion chelating agents, and the mass ratio of the three is 0.015-0.5:156.2-312.5:15.5-125; The artemisinin derivative is artesunate; The polymyxin is colistin; The metal ion complexing agent is EDTA-2Na.
